drugset / Trial / NCT03116828

A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures

NCT03116828

Phase 4 Completed 102 enrolled Sumitomo Pharma America, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A study of a drug to be used in addition with another drug to treat adults with Uncontrolled Partial-onset Seizures

Timeline

Start
2017-07-07
Primary completion
2019-06-06
Completion
2019-06-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Eslicarbazepine acetate Unknown 800 mg
Subject Eslicarbazepine acetate Unknown 1200 mg
Subject Eslicarbazepine acetate Unknown 1600 mg

Indications